Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
Washington University School of Medicine
Summary
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Eligibility Criteria: * Enrolled in the WU-PE-CGS study (IRB#202106129); that eligibility entails: * Diagnosis of cholangiocarcinoma * Diagnosis of multiple myeloma, must be African American * Diagnosis of colorectal cancer, must be African American and age 65 or older at time of diagnosis * At least 18 years old. * Able to understand an IRB-approved informed consent document and agree to participation * Have access to a personal computer, tablet or mobile device
Interventions
- OtherStandard developed materials
Participants will be given the option to receive different types of results from genomic sequencing. The choices available to them will be explained by research staff following a script that describes what each type of result means. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information
- OtherGenetics Advisor Decision Aid
Participants will be given the option to receive different types of results from genomic sequencing. The participants will be given access to a web-based decision aid that elicits participants' values and preferences for receiving results from cancer genomic sequencing to guide them making a decision about what types of results they would like to receive. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues.
Location
- Washington University School of MedicineSt Louis, Missouri